Ascendis Pharma A S (NASDAQ:ASND) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 3, 2016
Zacks Investment Research has downgraded Ascendis Pharma A S (NASDAQ:ASND) to Hold in a statement released on 10/03/2016.
On 9/26/2016, Wedbush released a statement for Ascendis Pharma A S (NASDAQ:ASND) bumped up the target price from $0.00 to $34.00 that suggested an upside of 0.73%.
Boasting a price of $19.91, Ascendis Pharma A S (NASDAQ:ASND) traded -0.95% lower on the day. With the last stock price close up 23.36% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Ascendis Pharma A S has recorded a 50-day average of $19.02 and a two hundred day average of $16.14. Volume of trade was down over the average, with 18,307 shares of ASND changing hands under the typical 52,880
With a total market value of $0, Ascendis Pharma A S has with a one year low of $11.92 and a one year high of $21.70 .
More About Ascendis Pharma A S (NASDAQ:ASND)
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.